Prof Thomas Flaig talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the randomised trial that examined chemotherapy regimens in muscle-invasive bladder cancer to assess the use of statistical biomarkers to predict which patients would respond to chemotherapy.
He describes the methodology behind this trial and the types of biomarkers that were used, along with their effectiveness. These included a biomarker for gemcitabine-cisplatin and one for MVAC.
Prof Flaig discusses future research opportunities, which include refining the use of the COXEN biomarker and correlating genetic information with this.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.